September 11, 2025

Relugolix for Metastatic Hormone-sensitive Prostate Cancer with Impending Paraplegia.

Key Points

Relugolix provided symptomatic relief for a 72-year-old man with metastatic prostate cancer and impending paraplegia.
After starting relugolix alongside zoledronic acid and steroids, symptoms improved within 24 hours, marking rapid testosterone suppression.
The use of injectable gonadotropin-releasing hormone agonists was avoided, mitigating risks and side effects tied to hormonal therapies.
This case indicates the potential for relugolix in urgent care scenarios for hormone-sensitive metastatic prostate cancer.

Abstract

Luteinizing hormone-releasing hormone agonists, used in advanced prostate cancer, can cause an initial testosterone surge and may inadequately suppress follicle-stimulating hormone, potentially promoting tumor growth. Injectable gonadotropin-releasing hormone (GnRH) antagonists avoid this surge but have drawbacks like injection-site reactions and monthly dosing. Relugolix, an oral GnRH antagonist, offers rapid testosterone suppression without flare and reduced cardiovascular risks. We report a 72-year-old man with suspected metastatic prostate cancer, presenting with severe neuritic pain and lower limb weakness. Relugolix, started before biopsy along with zoledronic acid and steroids, led to symptom relief within 24 h. This case supports Relugolix's utility in urgent hormone-sensitive metastatic prostate cancer care.

KI fragen

Bookmark

Cite This Study

Kumar et al. (Tue,) studied this question.

synapsesocial.com/papers/68c2a9c304ab598fffb89c85 https://doi.org/https://doi.org/10.4103/aam.aam_192_25

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

KI fragen

Bookmark